Denali Therapeutics (DNLI) Capital Leases (2024 - 2026)

Denali Therapeutics (DNLI) has 3 years of Capital Leases data on file, last reported at $5.5 million in Q1 2026.

• Capital Leases for Q1 2026 came in at $5.5 million, down 1.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 million (down 1.61% YoY), and the FY2025 annual result was $5.5 million, down 1.48% from the prior year.
• Capital Leases held at $5.5 million in Q1 2026 per DNLI's latest filing, from $5.5 million in the prior quarter.
• Over five years, Capital Leases peaked at $5.6 million in Q3 2024 and troughed at $5.5 million in Q1 2026.
• A 3-year average of $5.6 million and a median of $5.6 million in 2025 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2025 and 2026: Capital Leases declined 1.37% in 2025, then decreased 1.61% in 2026.
• A 3-year view of Capital Leases shows it stood at $5.6 million in 2024, then slipped by 1.48% to $5.5 million in 2025, then fell by 0.43% to $5.5 million in 2026.
• Business Quant data shows DNLI's Capital Leases at $5.5 million in Q1 2026, $5.5 million in Q4 2025, and $5.6 million in Q3 2025.